5.94 on the NASDAQ. This SniperIQ fundamentals page covers Neurogene's valuation, profitability (net margin 0.0%), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap$568M
Net Margin0.0%

Full research coverage

Frequently Asked Questions

What is Neurogene's market cap?

Neurogene (NGNE) has a market capitalization of approximately $568M, trading at

5.94 on the NASDAQ. Market cap moves with the live share price.

What is Neurogene's P/E ratio?

Neurogene's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 3.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Neurogene?

Neurogene runs a net profit margin of 0.0%, a gross margin of 0.0%, and an operating margin of 0.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

Does Neurogene pay a dividend?

Neurogene does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Neurogene financially healthy?

Neurogene carries a debt-to-equity ratio of 0.04x and a current ratio of 13.08x, with a market beta of 1.96. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Neurogene a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Neurogene (NGNE) the key facts are: market cap $568M, 52-week range 15.93-43.66. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Neurogene's full fundamentals live

Get Neurogene's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.